Partnership · 21 October 2026Nucelion TherapeuticsCell therapy manufacturer
Nucelion and VeGen Bio to make CAR-T in India
By Abha Lohia ·
PartnershipHealthcare & Life Sciences
- Nucelion Therapeutics, a Bharat Biotech subsidiary, makes cell and gene therapies for other drug developers
- It will transfer technology and manufacture VeGen Bio's dual-target CAR-T therapy for multiple myeloma
- The partners aim to cut production costs and widen patient access in India, with a path to global launches
What happened
- Partnership for CAR-T manufacturing in India.
- Candidate is VL-2511 for multiple myeloma.
- Covers technology transfer and clinical manufacturing.
Why it matters
- Lower costs can widen access to advanced therapy.
The business
- Contract development and manufacturing of cell and gene therapy.
- Wholly owned by Bharat Biotech.
What happens next
- Process optimisation and higher yields
All startup news on 21 October 2026 →
Is this Nucelion Therapeutics? Get your “Featured on StopDown” badge →